Search
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalApproved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
KB001
go.drugbank.com/drugs/DB05222InvestigationalKB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.
Tetrahydrofolic acid
go.drugbank.com/drugs/DB00116InvestigationalNutraceuticalTetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.
Levetiracetam
go.drugbank.com/drugs/DB01202ApprovedInvestigationalLevetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically un...
OPC-14523
go.drugbank.com/drugs/DB05422ExperimentalOPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Sebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalThis plasma kallikrein inhibitor works by reducing bradykinin, the substance that causes the characteristic swelling in HAE attacks [L53533]. The U.S.
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnIt was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.
Ocriplasmin
go.drugbank.com/drugs/DB08888ApprovedWithdrawnOcriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.